Evaluating the effectiveness of immunotherapy for advanced cancers
A Multicenter, Multiomics, Non-interventional, Real-world Study of the Efficacy and Safety of Immune Checkpoint Inhibitors as First-line Therapy for Advanced Malignancies
Xinqiao Hospital of Chongqing · NCT05862259
This study is testing how well immunotherapy works for people with advanced cancers like lung, stomach, and breast cancer by collecting and analyzing different types of medical data.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Xinqiao Hospital of Chongqing (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT05862259 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze data related to immunotherapy for advanced malignant tumors, including various solid tumors such as non-small-cell lung carcinoma, stomach, and breast cancers. The study will establish a comprehensive database that includes immunohistochemistry, gene detection, and imaging data, among other factors. Additionally, a predictive model will be developed to assess the validity of biomarkers and the overall effectiveness of immunotherapy in this patient population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-75 with stage IV advanced malignant tumors who can comply with the study protocol.
Not a fit: Patients with severe organ dysfunction or those with other malignant tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of immunotherapy's effectiveness and safety, potentially leading to improved treatment strategies for patients with advanced malignancies.
How similar studies have performed: Other studies have shown promise in using immunotherapy for advanced cancers, suggesting that this approach may be effective, although the specific predictive model being developed in this study is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent. 2. the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology. 3. the stage IV according to the eighth edition of IASLC. 4. PS 0-2, the expected survival \> 3 months. 5. the age of 18-75 years. 6. no contraindication to treatment with immune checkpoint inhibitors. Exclusion Criteria: 1. the patients' compliance was poor, which violated the rules of the trial; 2. the patients with severe dysfunction of vital organs (heart, liver and kidney) ; 3. the patients with other malignant tumors; 4. the researchers considered that the patients should not participate in other conditions of the trial.
Where this trial is running
Chongqing, Chongqing Municipality
- the second affiliated hospital of Army medical university — Chongqing, Chongqing Municipality, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Malignant Tumor, Immunotherapy, Artificial Intelligence